CardieX Limited announced on November 15 that it has acquired all the assets of Blumio, Inc., a Silicon Valley-based sensor technology startup, signifying the company’s continued investment in cardiovascular health monitoring technologies.
Blumio’s technology has the potential to significantly increase clinical performance for CardieX’s ecosystem of heart health monitoring solutions. As a result of the prior 3-year collaboration between Blumio and CardieX, the companies have already demonstrated Blumio’s sensor technology to be compatible with ATCOR’s patented SphygmoCor® arterial health technology.
Blumio CEO and Co-founder Catherine Liao joins CardieX as Chief Strategy Officer, with Blumio’s Head of Product & Operations Steve Braaten joining CardieX as Operations Director. Financial terms of the transaction were not disclosed.
Founded in 2015, Blumio is focused on developing wearable sensors and cardiovascular health algorithms, including blood pressure estimation that is not reliant on an inflatable cuff.
CardieX Limited is a global health technology company that focuses on hypertension, cardiovascular disease and other arterial health disorders. The company’s ATCOR division is the world leader in specialist medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the CONNEQT brand, the company develops wearables, digital solutions and devices for remote patient monitoring, decentralized clinical trials and home health.
According to the LevinPro HC database, this marks the 303rd eHealth transaction of 2022 and the 14th acquisition in the remote patient monitoring (RPM) subsector. This is a slight decrease from 2021 when there were 314 eHealth and 12 RPM transactions during the same period.
